Ischaemic stroke is a medical condition characterised by neuroinflammation and oxidative damage. Its treatment faces challenges related to drug delivery, particularly in overcoming the blood–brain barrier (BBB) and effectively targeting the stroke’s core. To overcome this challenge, we developed a novel nitric oxide (NO)-driven chemotactic nanomotor to increase the efficacy of ischaemic stroke treatment. The mesoporous nanomotor is loaded with tanshinone IIA, which actively inhibits pyroptosis and regulates the inflammatory response. Additionally, we conjugated a chemotactic nanomotor with a stroke-afflicted region-homing peptide, precisely guiding them to target damaged neurons within the ischaemic region. Notably, the chemotactic nanomotor reacts with ROS in the ischaemic microenvironment to produce NO, thereby not only reducing brain oxidative stress but also providing the driving force for deep brain penetration. The multifunctional nanomotor efficiently decreases reactive oxygen species (ROS) production and significantly mitigates inflammation-related pathology, thus imparting dual anti-oxidative and anti-inflammatory effects to remodel the ischaemic core microenvironment. In vitro and in vivo studies confirmed the synergistic role of antioxidant and anti-inflammatory effects in improving the ischaemic microenvironment. These findings suggest that an NO-driven nanomotor with synergistic therapeutic functions is highly effective to enhance therapeutic performance and clinical outcomes in ischaemic stroke.